Integral Health Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Integral Health Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-152,000	Closed	-$3.52M	–	103
2023 Q1	$3.52M	Sell	152,000 -23,000	-13%	-$548K	0.71%	51
2022 Q4	$4.58M	Buy	+175,000	New	+$3.88M	0.96%	39

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Integral Health Asset Management's KDNY Position: Q2 2023 in Review

Integral Health Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 152,000 shares — an estimated $3.52M sold.

Integral Health Asset Management first reported a position in KDNY in Q4 2022 and held it in 2 quarters. The position peaked at $4.58M in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Integral Health Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Integral Health Asset Management sold 152,000 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.52M.
Integral Health Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Integral Health Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $4.58M in Q4 2022.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Integral Health Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.